{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:56:43Z","timestamp":1780379803416,"version":"3.54.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.09.015","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T08:05:22Z","timestamp":1602317122000},"page":"7414-7416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-421X","authenticated-orcid":false,"given":"Walter E.P.","family":"Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.09.015_b0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","author":"Arbyn","year":"2018","journal-title":"Expert Rev Vaccines 2018"},{"key":"10.1016\/j.vaccine.2020.09.015_b0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","article-title":"Eradication of human papillomavirus and elimination of HPV-related diseases \u2013 scientific basis for global public health policies","volume":"18","author":"Lehtinen","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.015_b0015","doi-asserted-by":"crossref","unstructured":"Arbyn M., Xu L., Simoens C., Martin-Hirsch, P.P.L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD009069. https:\/\/dx.doi.org\/10.1002\/14651858.CD009069.pub3.","DOI":"10.1002\/14651858.CD009069.pub3"},{"key":"10.1016\/j.vaccine.2020.09.015_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2020.09.015_b0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.vaccine.2020.09.015_b0030","first-page":"e12367","article-title":"Toward a better understanding of the relationship between influenza vaccine effectiveness against specific and non-specific endpoints and vaccine effectiveness against influenza infection","volume":"14","author":"Nauta","year":"2017","journal-title":"Epidemiol Biostatist Publ Hlth"},{"key":"10.1016\/j.vaccine.2020.09.015_b0035","first-page":"l116","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.09.015_b0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: A Danish nationwide cohort study","volume":"70","author":"Verdoodt","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.015_b0045","article-title":"Estimation of vaccine efficacy and critical vaccination coverage in partially observed outbreaks","volume":"2013","author":"van Boven","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2020.09.015_b0050","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminum salt combination (AS04) compared to aluminum salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.015_b0055","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20311579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20311579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:29Z","timestamp":1759402169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20311579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":11,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20311579"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}